Article

Beta-blocker effective to manage regression after refractive surgery

Lisbon, Portugal - Treatment with a topical beta-blocker is effective for preventing regression after LASIK to treat myopia. However, there is no way to predict which patients will respond to the therapy, according to Takayoshi Suzuki, MD, who reported his findings Tuesday at the European Society of Cataract and Refractive Surgeons meeting.

Lisbon, Portugal - Treatment with a topical beta-blocker is effective for preventing regression after LASIK to treat myopia. However, there is no way to predict which patients will respond to the therapy, according to Takayoshi Suzuki, MD, who reported his findings Tuesday at the European Society of Cataract and Refractive Surgeons meeting.

Dr. Suzuki and colleagues from the Department of Ophthalmology, Tokyo Dental College, Suidobashi Hospital, Tokyo, studied 41 eyes of 30 patients (18 women, 12 men) who had undergone LASIK for myopia. Regression occurred in all of these eyes and the patients received 0.5% topical timolol (Santen) once daily for at least 3 months. Following the treatment, the patients were divided into two groups based on the treatment response. Group 1 included patients whose vision improved by 1 line or more and Group 2 included patients who showed no improvement.

Dr. Suzuki reported that the mean preoperative manifest refraction spherical equivalent was –7 ± 0.57 D. Twenty-four eyes (58.5%) in Group 1 improved and 17 eyes in Group 2 (41.5%) either stayed the same or regressed.

“We found that topical timolol was effective to prevent regression after LASIK. However, there is no way to predict which patients will respond to treatment. The patient age, the preoperative spherical equivalent, and the amount of time after surgery were not factors that affected the results,” Dr. Suzuki concluded.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.